Pharsight

Recently Added Drugs

1. Adzenys Xr-odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9839619 NEOS THERAPS Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles
Jun, 2032

(8 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of ADZENYS XR-ODT before it's drug patent expiration?
More Information on Dosage

ADZENYS XR-ODT family patents

Family Patents

2. Auvelity patents expiration

Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969421 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage

AUVELITY family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Ayvakit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11964980 BLUEPRINT MEDICINES Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
Apr, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-864) Jun 16, 2024
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
New Indication(I-912) May 22, 2026

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

Family Patents

4. Cequa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951153 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(12 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

CEQUA family patents

Family Patents

5. Drospirenone patents expiration

Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951213 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 29, 2025

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

DROSPIRENONE family patents

Family Patents

6. Duvyzat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7329689 ITALFARMACO SPA Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester
Jan, 2025

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421184 ITALFARMACO SPA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Feb, 2032

(7 years from now)

US9867799 ITALFARMACO SPA Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy
Feb, 2032

(7 years from now)

US10688047 ITALFARMACO SPA Physically and chemically stable oral suspensions of givinostat
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2029
Orphan Drug Exclusivity(ODE-473) Mar 21, 2031

Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient

NCE-1 date: 21 March, 2028

Market Authorisation Date: 21 March, 2024

Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat

Dosage: SUSPENSION;ORAL

More Information on Dosage

DUVYZAT family patents

Family Patents

7. Edurant Ped patents expiration

EDURANT PED's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065198 JANSSEN PRODS Dispersible compositions
Oct, 2037

(13 years from now)

Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 March, 2024

Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral treatment-naive patients 2 years of age and older, weighing at least 14kg, with hiv-1 rna less th...

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

EDURANT PED family patents

Family Patents

8. Eligard Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11931559 TOLMAR Systems and methods for mixing syringe valve assemblies
Dec, 2041

(17 years from now)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 14 December, 2004

Treatment: NA

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

ELIGARD KIT family patents

Family Patents

9. Entresto Sprinkle patents expiration

ENTRESTO SPRINKLE's oppositions filed in EPO
ENTRESTO SPRINKLE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877938 NOVARTIS Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS Methods of treatment and pharmaceutical composition
Jan, 2025

(7 months from now)

US9388134 NOVARTIS Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(2 years from now)

US10722471 NOVARTIS Galenic formulations of organic compounds
Feb, 2037

(12 years from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: Treatment of heart failure; Treatment of heart failure with oral pellets

Dosage: CAPSULE, PELLETS;ORAL

More Information on Dosage

ENTRESTO SPRINKLE family patents

Family Patents

10. Erleada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11963952 JANSSEN BIOTECH Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
Jan, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of patients with metastatic castration sensitive prostate cancer

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

11. Evrysdi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11938136 GENENTECH INC Compositions for treating spinal muscular atrophy
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-334) Aug 07, 2027
New Chemical Entity Exclusivity(NCE) Aug 07, 2025
Orphan Drug Exclusivity(ODE-400) May 27, 2029
New Patient Population(NPP) May 27, 2025
M(M-270) Oct 03, 2026

Drugs and Companies using RISDIPLAM ingredient

NCE-1 date: 07 August, 2024

Market Authorisation Date: 07 August, 2020

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

EVRYSDI family patents

Family Patents

12. Fabhalta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951101 NOVARTIS Methods of using factor B inhibitors
Jul, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2028
Orphan Drug Exclusivity(ODE-456) Dec 05, 2030

Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient

NCE-1 date: 06 December, 2027

Market Authorisation Date: 05 December, 2023

Treatment: Treatment of paroxysmal nocturnal hemoglobinuria (pnh) by administration of 200 mg of iptacopan twice daily

Dosage: CAPSULE;ORAL

More Information on Dosage

FABHALTA family patents

Family Patents

13. Fensolvi Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11931559 TOLMAR Systems and methods for mixing syringe valve assemblies
Dec, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-829) May 01, 2023

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 01 May, 2020

Treatment: NA

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

FENSOLVI KIT family patents

Family Patents

14. Lumisight patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9763577 LUMICELL Imaging agent for detection of diseased cells
Sep, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155471 LUMICELL Methods and systems for spatially identifying abnormal cells
Oct, 2031

(7 years from now)

US9532835 LUMICELL Methods and system for image guided cell ablation with microscopic resolution
Dec, 2031

(7 years from now)

US10285759 LUMICELL Methods and system for image guided cell ablation with microscopic resolution
Dec, 2031

(7 years from now)

US9032965 LUMICELL Methods and system for image guided cell ablation with microscopic resolution
Dec, 2031

(7 years from now)

Drugs and Companies using PEGULICIANINE ACETATE ingredient

Market Authorisation Date: 17 April, 2024

Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

LUMISIGHT family patents

Family Patents

15. Lutathera patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11904027

(Pediatric)

AAA USA INC Stable, concentrated radionuclide complex solutions
Jan, 2039

(14 years from now)

US10596278

(Pediatric)

AAA USA INC Stable, concentrated radionuclide complex solutions
Jan, 2039

(14 years from now)

US10596276

(Pediatric)

AAA USA INC Stable, concentrated radionuclide complex solutions
Jan, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-166) Jan 26, 2025
Pediatric Exclusivity(PED) Jul 26, 2025
New Chemical Entity Exclusivity(NCE) Jan 26, 2023

Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient

NCE-1 date: 26 July, 2024

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

LUTATHERA family patents

Family Patents

16. Lybalvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951111 ALKERMES INC Immediate release multilayer tablet
Nov, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: 28 May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating schizophrenia by administering a bilayer tablet comprising olanzapine and samidorphan

Dosage: TABLET;ORAL

More Information on Dosage

LYBALVI family patents

Family Patents

17. Mayzent patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11944602 NOVARTIS Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 26, 2024
M(M-274) Mar 01, 2025

Drugs and Companies using SIPONIMOD ingredient

NCE-1 date: 27 March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults receiving or who may ...

Dosage: TABLET;ORAL

How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage

MAYZENT family patents

Family Patents

18. Multrys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11975022 AM REGENT NA
Jul, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 June, 2021

Treatment: Neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or ...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

MULTRYS family patents

Family Patents

19. Mycapssa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969471 CHIESI Pharmaceutical compositions and related methods of delivery
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-474) Jun 26, 2027
New Product(NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

MYCAPSSA family patents

Family Patents

20. Myfembree patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11957684 MYOVANT SCIENCES Treatment of heavy menstrual bleeding associated with uterine fibroids
Sep, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2025
New Product(NP) May 26, 2024
M(M-289) Jan 27, 2026
New Indication(I-898) Aug 05, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 18 December, 2024

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

Family Patents

21. Nexletol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11744816 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 21, 2025

Drugs and Companies using BEMPEDOIC ACID ingredient

NCE-1 date: 22 February, 2024

Market Authorisation Date: 21 February, 2020

Treatment: A method of lowering ldl-c or reducing the risk of cardiovascular disease in patients with familial hypercholesterolemia using 180 mg bempedoic acid and 10 mg ezetimibe

Dosage: TABLET;ORAL

More Information on Dosage

NEXLETOL family patents

Family Patents

22. Nextstellis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11964055 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(12 years from now)

US11957694 MAYNE PHARMA Orodispersible dosage unit containing an estetrol component
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2026

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

NCE-1 date: 15 April, 2025

Market Authorisation Date: 15 April, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

NEXTSTELLIS family patents

Family Patents

23. Ogsiveo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951958 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Mar, 2025

(9 months from now)

US7795447 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(1 year, 2 months from now)

US7342118 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(1 year, 2 months from now)

US11845732 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10710966 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10590087 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US10941118 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11820748 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11884634 SPRINGWORKS Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
Aug, 2039

(15 years from now)

US11884635 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11905255 SPRINGWORKS Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Aug, 2039

(15 years from now)

US11504354 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Jul, 2042

(18 years from now)

US11612588 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Jul, 2042

(18 years from now)

US11844780 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Sep, 2042

(18 years from now)

US11807611 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Sep, 2042

(18 years from now)

US11872211 SPRINGWORKS Treatments with nirogacestat
May, 2043

(19 years from now)

US11957662 SPRINGWORKS Treatments with nirogacestat
May, 2043

(19 years from now)

US11925620 SPRINGWORKS Treatments with nirogacestat
May, 2043

(19 years from now)

US11938116 SPRINGWORKS Treatments with nirogacestat
May, 2043

(19 years from now)

US11951096 SPRINGWORKS Treatments with nirogacestat
May, 2043

(19 years from now)

US11925619 SPRINGWORKS Treatments with nirogacestat
May, 2043

(19 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Nov 27, 2030
New Chemical Entity Exclusivity(NCE) Nov 27, 2028
Orphan Drug Exclusivity(ODE-452) Nov 27, 2030

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: Treatment of adult patients with progressing desmoid tumors

Dosage: TABLET;ORAL

More Information on Dosage

OGSIVEO family patents

Family Patents

24. Ojemda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8293752 DAY ONE BIOPHARMS Compounds useful as Raf kinase inhibitors
Aug, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10426782 DAY ONE BIOPHARMS Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation
Jun, 2035

(11 years from now)

Drugs and Companies using TOVORAFENIB ingredient

Market Authorisation Date: 23 April, 2024

Treatment: NA

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

More Information on Dosage

OJEMDA family patents

Family Patents

25. Opsynvi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(1 year, 6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Sep, 2026

(2 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2027
Orphan Drug Exclusivity(ODE-475) Mar 22, 2031

Drugs and Companies using MACITENTAN; TADALAFIL ingredient

Market Authorisation Date: 22 March, 2024

Treatment: Use of the combination of macitentan and tadalafil for the chronic treatment of adults with pulmonary arterial hypertension; Method of treating pulmonary arterial hypertension comprising administering...

Dosage: TABLET;ORAL

More Information on Dosage

OPSYNVI family patents

Family Patents

26. Otezla patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7427638

(Pediatric)

AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Aug, 2028

(4 years from now)

US9872854

(Pediatric)

AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
Nov, 2034

(10 years from now)

US10092541

(Pediatric)

AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-248) Jul 19, 2026
New Indication(I-884) Dec 20, 2024
M(M-299) Jul 20, 2026
New Chemical Entity Exclusivity(NCE) Mar 21, 2019
New Indication(I-694) Sep 23, 2017
New Indication(I-803) Jul 19, 2022
M(M-257) Apr 10, 2023

Drugs and Companies using APREMILAST ingredient

NCE-1 date: 21 March, 2018

Market Authorisation Date: 21 March, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage

OTEZLA family patents

Family Patents

27. Oxbryta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11944612 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-281) Nov 25, 2026
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 14 October, 2022

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 10

Dosage: TABLET;ORAL

More Information on Dosage

OXBRYTA family patents

Family Patents

28. Oxycontin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11964056 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-153) Apr 16, 2016
New Patient Population(NPP) Aug 13, 2018

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2010

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

OXYCONTIN family patents

Family Patents

29. Pedmark patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11964018 FENNEC PHARMS INC Therapeutic uses for sodium thiosulfate formulations
Jul, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 20, 2025
Orphan Drug Exclusivity(ODE-384) Sep 20, 2029

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: Use of a pharmaceutical composition of about 0.5m sodium thiosulfate, about 0.004m boric acid, and a ph of between about 6.5 and 8.9 for reducing ototoxicity in a pediatric patient receiving cisplatin...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PEDMARK before it's drug patent expiration?
More Information on Dosage

PEDMARK family patents

Family Patents

30. Ponvory patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951097 JANSSEN PHARMS Methods of treating multiple sclerosis
Oct, 2042

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults being treated with a ...

Dosage: TABLET;ORAL

More Information on Dosage

PONVORY family patents

Family Patents

31. Qinlock patents expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969415 DECIPHERA PHARMS (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Dec, 2040

(16 years from now)

US11969414 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Feb, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2025
Orphan Drug Exclusivity(ODE-298) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with itraconazole

Dosage: TABLET;ORAL

More Information on Dosage

QINLOCK family patents

Family Patents

32. Radicava Ors patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11957660 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-144) May 12, 2029
New Product(NP) May 12, 2025

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage

RADICAVA ORS family patents

Family Patents

33. Retevmo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10112942 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10584124 LOXO ONCOL ELI LILLY Crystalline forms
Oct, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137124 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10172851 LOXO ONCOL ELI LILLY Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Oct, 2037

(13 years from now)

US10786489 LOXO ONCOL ELI LILLY Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(14 years from now)

Drugs and Companies using SELPERCATINIB ingredient

Market Authorisation Date: 10 April, 2024

Treatment: Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with a rearranged during transfection (ret) gene fusion, as detected by an fda-approved test; Treatme...

Dosage: TABLET;ORAL

More Information on Dosage

RETEVMO family patents

Family Patents

34. Slynd patents expiration

Can you believe SLYND received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951213 EXELTIS USA INC Synthetic progestogens and pharmaceutical compositions comprising the same
Jun, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2022

Drugs and Companies using DROSPIRENONE ingredient

Market Authorisation Date: 23 May, 2019

Treatment: Prevention of pregnancy in females of reproductive age

Dosage: TABLET;ORAL

How can I launch a generic of SLYND before it's drug patent expiration?
More Information on Dosage

SLYND family patents

Family Patents

35. Sunlenca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11944611 GILEAD SCIENCES INC Capsid inhibitors for the treatment of HIV
Jun, 2041

(17 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11944611 GILEAD SCIENCES INC Capsid inhibitors for the treatment of HIV
Jun, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 22 December, 2026

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: TABLET;ORAL; SOLUTION;SUBCUTANEOUS

More Information on Dosage

SUNLENCA family patents

Family Patents

36. Sunosi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11969404 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having a history of bipolar disorders and moderate or severe renal impairment

Dosage: TABLET;ORAL

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

37. Symdeko (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951212 VERTEX PHARMS INC Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Apr, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-173) Feb 12, 2025
Orphan Drug Exclusivity(ODE-247) Jun 21, 2026
Orphan Drug Exclusivity(ODE-335) Dec 21, 2027
New Chemical Entity Exclusivity(NCE) Feb 12, 2023
New Patient Population(NPP) Jun 21, 2022

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

NCE-1 date: 12 February, 2022

Market Authorisation Date: 21 June, 2019

Treatment: Treatment of cystic fibrosis in patients age 6 and older who are homozygous for the f508del mutation or have at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor with a compositi...

Dosage: TABLET;ORAL

More Information on Dosage

SYMDEKO (COPACKAGED) family patents

Family Patents

38. Tavneos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951214 CHEMOCENTRYX Capsule formulations
Nov, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-377) Oct 07, 2028
New Chemical Entity Exclusivity(NCE) Oct 07, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 07 October, 2025

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

TAVNEOS family patents

Family Patents

39. Tralement patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11975022 AM REGENT NA
Jul, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 June, 2021

Treatment: Adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or cont...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

TRALEMENT family patents

Family Patents

40. Tryvio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8324232 IDORSIA 4-pyrimidinesulfamide derivative
Sep, 2029

(5 years from now)

US10919881 IDORSIA Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
Feb, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11174247 IDORSIA Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
Nov, 2037

(13 years from now)

US11787782 IDORSIA Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
Mar, 2038

(13 years from now)

US11680058 IDORSIA Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan
Jul, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 22, 2029

Drugs and Companies using APROCITENTAN ingredient

NCE-1 date: 22 March, 2028

Market Authorisation Date: 19 March, 2024

Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...

Dosage: TABLET;ORAL

More Information on Dosage

TRYVIO family patents

Family Patents

41. Ubrelvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11925709 ABBVIE Tablet formulation for CGRP active compounds
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 24 December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

UBRELVY family patents

Family Patents

42. Vafseo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47437 AKEBIA Prolyl hydroxylase inhibitors and methods of use
Jun, 2027

(3 years from now)

US8598210 AKEBIA Prolyl hydroxylase inhibitors and methods of use
Jun, 2027

(3 years from now)

US11065237 AKEBIA Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Nov, 2034

(10 years from now)

US9701636 AKEBIA Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Nov, 2034

(10 years from now)

US10149842 AKEBIA Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Nov, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940773 AKEBIA Prolyl hydroxylase inhibitors and methods of use
Jun, 2027

(3 years from now)

US8323671 AKEBIA Prolyl hydroxylase inhibitors and methods of use
Apr, 2028

(3 years from now)

US11857543 AKEBIA Compositions and methods for treating anemia
Jun, 2034

(10 years from now)

US9987262 AKEBIA Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Nov, 2034

(10 years from now)

US11324734 AKEBIA Compositions and methods for treating anemia
Mar, 2036

(11 years from now)

US11844756 AKEBIA Compositions and methods for treating anemia
Mar, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 27, 2029

Drugs and Companies using VADADUSTAT ingredient

NCE-1 date: 27 March, 2028

Market Authorisation Date: 27 March, 2024

Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months

Dosage: TABLET;ORAL

More Information on Dosage

VAFSEO family patents

Family Patents

43. Xospata patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11938133 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

US11938132 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

US11938131 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

US11938130 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

US11944620 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-222) Nov 28, 2025
New Chemical Entity Exclusivity(NCE) Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: 28 November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage

XOSPATA family patents

Family Patents

44. Zepbound patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

US11918623 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 08, 2026
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEPBOUND family patents

Family Patents